Emmerich Joseph, Fiessinger Jean-Noël
Université Paris-Descartes, INSERM U765, Service de Médecine Vasculaire - HTA, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 Paris 15.
Bull Acad Natl Med. 2006 Mar;190(3):667-80; discussion 680-1, 683-4.
Critical limb ischemia (CLI) is associated with a high risk of amputation and death. For patients who cannot be surgically revascularized, medical options include prostanoids, spinal cord stimulation and lumbar sympathectomy, but none of these treatments has a demonstrated impact on the amputation rate at six months. Gene and cell therapy, aimed at stimulating angiogenesis, have mainly been tested in phase I and II clinical trials. These approaches appear to be feasible and safe in the short-term, but large randomized studies are necessary to demonstrate their clinical benefits and long-term safety.
严重肢体缺血（CLI）与截肢和死亡的高风险相关。对于无法通过手术实现血管再通的患者，药物治疗选择包括前列腺素、脊髓刺激和腰交感神经切除术，但这些治疗方法均未显示对六个月时的截肢率有影响。旨在刺激血管生成的基因和细胞疗法主要在I期和II期临床试验中进行了测试。这些方法在短期内似乎是可行且安全的，但需要大型随机研究来证明其临床益处和长期安全性。
